Research!America

Research!America
Name	Research!America
Formation	1989
Type	Nonprofit advocacy organization
Headquarters	Alexandria, Virginia
Leader title	President and CEO
Leader name	Mary Woolley
Area served	United States
Focus	Medical research advocacy

Research!America is a nonprofit advocacy organization dedicated to increasing public support and funding for health and medical research in the United States. It engages policymakers, the biomedical community, patient groups, and the public through campaigns, polling, coalition-building, and communications to influence research funding and policy priorities. Its work intersects with federal agencies, private foundations, industry stakeholders, and professional associations involved in biomedical science and public health.

History

Founded in 1989 amid debates over federal research funding and biomedical innovation, the organization emerged during a period marked by budget debates in the United States Congress, budget reconciliation acts, and discussions surrounding the role of the National Institutes of Health and the Centers for Disease Control and Prevention in public health. Early efforts coincided with initiatives led by leaders in the pharmaceutical and academic sectors, and with major patient advocacy movements for conditions such as HIV/AIDS and breast cancer. The organization has operated through multiple administrations, engaging with cabinets and agencies including the Department of Health and Human Services, the Office of Management and Budget, and the White House Office of Science and Technology Policy. Over its history it has partnered with professional societies like the American Medical Association and research institutions such as the Johns Hopkins University and the Massachusetts Institute of Technology.

Mission and Activities

The stated mission centers on advocacy for increased investment in biomedical, behavioral, and public health research to improve health outcomes and economic competitiveness. Activities include public opinion polling, producing policy reports, organizing events such as advocacy days on Capitol Hill, and coordinating coalitions with patient groups including American Cancer Society Cancer Action Network, Alzheimer's Association, and rare disease organizations that have engaged with the Food and Drug Administration on regulatory issues. Communications efforts leverage relationships with media outlets like The New York Times, The Washington Post, and broadcast networks to elevate research funding debates tied to legislation such as appropriations acts and omnibus spending bills. The organization also conducts outreach to universities, academic health centers, medical societies, and biotechnology companies including those represented by PhRMA and the Biotechnology Innovation Organization.

Advocacy and Policy Impact

Advocacy strategies combine grassroots mobilization, stakeholder coalitions, and targeted campaigns aimed at members of the United States Congress, particularly committees like the House Appropriations Committee and the Senate Appropriations Committee, as well as authorizing committees such as the House Energy and Commerce Committee. The organization has lobbied for appropriations increases for agencies including the National Institutes of Health, the National Science Foundation, and the Department of Veterans Affairs (United States). It has influenced discussions on legislation such as the 21st Century Cures Act and budget agreement negotiations. Policymakers from both major parties, including members of the Democratic Party (United States) and Republican Party (United States), have been targets of outreach, and the organization frequently briefs staff from congressional offices, executive branch agencies, and presidential transition teams. Its polling and issue briefs have been cited in hearings before panels like the Senate Health, Education, Labor and Pensions Committee.

Programs and Initiatives

Key programs include annual public opinion surveys, the "Be The Voice" grassroots program, and campaign initiatives centered on specific disease areas such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, and oncology research. It organizes events like national science advocacy days and collaborates on award programs and recognitions with institutions similar to the National Academy of Sciences and the Association of American Universities. Educational initiatives engage students and early-career researchers at institutions such as Harvard University, Stanford University, and the University of California, San Francisco. Partnerships with industry consortia and philanthropic organizations such as the Bill & Melinda Gates Foundation and the Robert Wood Johnson Foundation have supported programmatic work on global health and translational research.

Organizational Structure and Funding

Structured as a nonprofit advocacy entity, governance includes a board of directors composed of leaders from academia, industry, patient advocacy, and philanthropy. Executive leadership liaises with advisory councils and partner organizations like the Association of American Medical Colleges and the Federation of American Societies for Experimental Biology. Funding streams historically derive from a mix of corporate contributions from biotechnology and pharmaceutical firms, philanthropic grants, membership dues, and event sponsorships. Major donor relationships have included corporations and foundations that overlap with those supporting biomedical research policy initiatives, and these funding relationships influence programming priorities and coalition composition.

Criticism and Controversies

Critiques have centered on potential conflicts of interest stemming from industry funding and the alignment of advocacy priorities with corporate stakeholders in biotechnology and pharmaceuticals. Commentators and watchdog groups, including think tanks and investigative journalists at outlets such as ProPublica and journalistic investigations in Science (journal), have questioned the transparency of funding sources and the balance between public and private interests. Debates have arisen over messaging around tax incentives, exclusive licensing policies at universities like Stanford University and University of California campuses, and advocacy positions on regulatory pathways involving the Food and Drug Administration. Some academic critics from institutions such as Columbia University and Yale University have argued for more explicit safeguards against industry influence, while policymakers and patient advocates have defended the role of cross-sector partnerships in accelerating translational science.

Category:Non-profit organizations based in the United States